Alzheimer's Drug Research: Where Is It Headed?

By Starr, Cynthia | Drug Topics, December 14, 1992 | Go to article overview

Alzheimer's Drug Research: Where Is It Headed?

Starr, Cynthia, Drug Topics

The families of patients with Alzheimer's disease are praying for a drug that will reverse--or even stall--the dreadful mental deterioration associated with the disorder. While plenty of compounds are under scrutiny, the two that are furthest along in development have yet to make it over the finish line.

"There are no drugs on the market today that have been conclusively proven to be effective in treating Alzheimer's disease," M. Lynn Crismon, professor and head, clinical division, University of Texas at Austin College of Pharmacy, told attendees at last month's American Society of Consultant Pharmacists 3rd Annual Meeting and Exhibition in Orlando, Fla. Speaking at a Parke-Davis sponsored session called Horizons in Drug Therapy of Alzheimer's Disease, he noted that "at least 35 to 36 different drugs are in research and development."

Cholonergic agents: "Some have already bitten the dust, some are still being looked at, and some are getting close to marketing," he told the crowd. Most work has been done with cholinergic agents, as patients with Alzheimer's have been found to have dramatic deficits of the chemical messenger, acetylcholine. Compounds under scrutiny are aimed at enhancing the supply of the neurotransmitter. For example, Warner-Lambert Co.'s tacrine or Cognex (also known as tetrahydroaminoacridine or THA) is designed to boost ACH levels by inhibiting cholinesterase, an enzyme that splits acetylcholine into choline and acetic acid.

Tacrine is "to the best of my knowledge, the first real modern joint venture between the National Institutes of Health and a pharmaceutical company," Crismon said. Warner-Lambert was commissioned to run multicenter trials and, ultimately, to submit a New Drug Application. However, he added, "a lot of studies have been plagued with all kinds of methodological problems, so you see all kinds of mixed results; some positive, some negative. It's been extremely difficult to be able to make any conclusions about drug efficacy." (See following story.) (story omitted)

As a result, the compound has yet to be approved. In 1991, the Food & Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee recommended that the drug not be approved without further clinical study. Later that year, the FDA authorized a treatment IND program that currently allows thousands of patients access to the drug. Since then, new, more formal, research has gotten under way, including a large, 30-week, double-blind, placebo-controlled, parallel-group study due to finish up early in 1993.

The results of one of two studies originally submitted in support of the NDA were revived in the lay press after they appeared in the Oct. 29 New England Journal of Medicine (the study was carried out between 1987 and 1990). Although patients taking tacrine showed a decreased rate of decline with one objective measure of cognitive function, the clinicians assessing the patients' progress found no difference between those on tacrine and those on placebo, noted Crismon.

Promising findings: The findings were more promising in a study appearing in the Nov. 11 issue of JAMA. The 12-week research represents "the best designed tacrine study," Crismon related. Patients taking 80 mg of tacrine per day did "extremely well." Objective measurements of cognitive function showed improvement, as did the investigators' and caregivers' assessments of the patient.

"In a 12-week period," Crismon said, "researchers were able to reverse the average decline you'd usually see over a six-month period. That's a fairly dramatic finding. None of the earlier studies have been nearly this positive."

Tacrine does cause adverse reactions. "The hepatotoxicity is real; it's there," Crismon said. you see it in the studies; you will see it if the drug is approved." Other reported ADRs include nausea and vomiting, headache, diarrhea, abdominal pain, dyspepsia, and rhinitis.

Another cholinesterase inhibitor, Hoechst-Roussel Pharmaceuticals Inc. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Cite this article

Cited article

Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25,

Note: primary sources have slightly different requirements for citation. Please see these guidelines for more information.

Cited article

Alzheimer's Drug Research: Where Is It Headed?


Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25,

    New feature

    It is estimated that 1 in 10 people have dyslexia, and in an effort to make Questia easier to use for those people, we have added a new choice of font to the Reader. That font is called OpenDyslexic, and has been designed to help with some of the symptoms of dyslexia. For more information on this font, please visit

    To use OpenDyslexic, choose it from the Typeface list in Font settings.

    OK, got it!

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search


    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.